Skip to content

Amygdala Insula Retraining (AIR) in the Management of Mold Illness Symptoms

Amygdala Insula Retraining (AIR) in the Management of Mold Illness Symptoms

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07425431
Enrollment
134
Registered
2026-02-20
Start date
2025-02-15
Completion date
2025-08-15
Last updated
2026-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mold Illness

Brief summary

The goal of the study is to compare a mind body intervention against usual care in patients with fatigue with mold illness. Our research questions include: * Is the mind body intervention additive to usual care in mold illness * Can the mind body intervention change self-reported overall wellness, and wearable device metrics such as heart rate variability

Detailed description

More than a substantial proportion of individuals in the United States with a history of chronic exposure to water-damaged buildings and indoor mold report persistent, disabling symptoms that extend well beyond the period of initial exposure. This condition is often described as mold-related illness or biotoxin-associated illness. Symptoms commonly include fatigue, post-exertional malaise (PEM), cognitive dysfunction, autonomic and cardiovascular disturbances, respiratory and sinus symptoms, gastrointestinal dysregulation, dermatologic manifestations, and heightened sensory sensitivity. These symptoms are heterogeneous, frequently involve multiple organ systems, and overlap in extent and severity with other neuro-immune conditions such as Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Mold-related illness, similar to ME/CFS, is likely to pose a significant burden on both healthcare systems and patient quality of life. Despite growing clinical recognition, substantial gaps remain in understanding individual susceptibility, pathophysiology, and optimal treatment approaches. Current hypotheses suggest that immune dysregulation, neuroinflammation, autonomic nervous system imbalance, and persistent stress-response activation may play central roles in symptom perpetuation. Pharmacologic and detoxification-based interventions are often heterogeneous in response, and the development or validation of targeted treatments remains limited. Emerging evidence increasingly supports the role of the mind-body connection in modulating autonomic, central, and peripheral nervous system activity, immune function, and gastrointestinal regulation. Holistic strategies such as mindfulness, meditation, and amygdala and insula retraining (AIR) have demonstrated objective, measurable effects on heart rate variability, fatigue, pain, mood, quality of life, anxiety, depression, and gastrointestinal symptoms across related neuro-immune conditions. Proposed mechanisms include vagus nerve activation, autonomic nervous system rebalancing, stress reduction, and downstream immune modulation. AIR is based on the principle that environmental insults, including mold and biotoxin exposure, can sensitize threat-processing centers of the brain such as the amygdala, resulting in persistent hypervigilance and maladaptive neuroendocrine and immune signaling. This state may perpetuate neuroinflammation, dysautonomia, and symptom chronicity even after removal from exposure. AIR aims to de-sensitize these neural circuits, interrupting maladaptive feedback loops and reducing excessive hormonal and cytokine release. Our clinical group has recommended AIR in individuals with mold-related illness and has observed favorable anecdotal clinical responses. This intervention is readily accessible, non-invasive, and carries minimal risk. We therefore aim to conduct a pilot study of AIR in individuals with mold-related illness to generate preliminary data to support a larger, federally funded clinical trial. Our specific aims are: * Identify 150 subjects who have received a positive Mycotoxin test in the last year and experience symptoms of mold illness. Subjects will be randomized to either 1. AIR + standard of care or 2. Standard of care/control. Individuals in this latter arm will be waitlisted to receive the AIR intervention after they complete the study. * Collect standard questionnaires at baseline, three, and six months to capture symptoms and compare changes over time across the two study arms. * Collect objective wearable data to explore potential mediating mechanisms such as heart rate variability

Interventions

Mind body intervention

Sponsors

Chronic Conditions Research Fund
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Ages 18-80 * Confirmed mold illness through a positive mold mycotoxin test from October 2023-January 2025 OR who are receiving active treatment for mold illness under the care of an MD or ND. * Able to speak English * Able to access internet

Exclusion criteria

\- Previous experience with brain retraining programs

Design outcomes

Primary

MeasureTime frameDescription
Mold IQ QuestionnaireBaseline (Week 0) to post-intervention (Week 12)
Heart Rate VariabilityBaseline (Week 0) to post-intervention (Week 12)HRV collected via wearable devices

Secondary

MeasureTime frame
Multidimensional Fatigue Inventory (MFI)Baseline (Week 0) to post-intervention (Week 12)
PROMIS-29Baseline (Week 0) to post-intervention (Week 12)
EuroQol 5 Dimension (EQ-5D)Baseline (Week 0) to post-intervention (Week 12)
Hospital Anxiety and Depression Scale (HADS)Baseline (Week 0) to post-intervention (Week 12)

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 21, 2026